Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > The call & mid afternoon update
View:
Post by canadafan on Nov 03, 2023 5:26pm

The call & mid afternoon update

First the call.
There were more analysts questions than we have heard in a long time.
The question around partnerships was asked. It was phrased clear & with little wiggle room.
The answer was qualified by " we can not preict when"
They also DID address the change of the 90 day window, by stating both the ":precision promise & $5 million grant" came late in the game.
They did mention multiple discussions with multiple stakeholders & working towards the best overall long term opportunitiy for Pelareorep. Across a broader range of applications.
My commentary on that.
The details are in the details. Some may argue " what negotiations & with who"
They said very clearly in a public recorded form " they are" not " we hope to," be in discussions.
subtle but huge difference.
Assuming there becomes a total buy- out, that information & negotiations trail would become part of presentation to shareholders.
Board meeting have minutes & even " in camera" items like negotiations are a matter of record.
so any argument of scam, fraud etc is a 100% red herring. 

saying that, we know they are in partership discussions. " buy out " never discussed & wont be until/ if that /gets closer to reality.
Again, first document of any buyout negotiations is a NDA.
keeping in mind that every statement they make is vetted by lawyers.
todays message could have discussed many other things.
CAR-t, the ongoing Incyte trial, the mm trial not discussed.
The China partership. Not discussed.
The $17 million was discussed in financials. No details.
Matt worked hard at providing laser focus on 3 points.
ironically I can not remember the 3 points.
I think , getting ready for panc phase 3, the ever increasing MOA data & the recent biomarker results.?
 

It was significantly different than previous conference calls.

question , why?

One coukd argue  either side. 

Too much data confuses?
Most forgotten items could be dead the water or one signature away of  a B.D.  Partnership.
The onky thing I know for sure. Using comparables in the biotech market. Onc is extremely undervalued.
Matt did mention a board meeting yesterday.
would like to be a fly on that wall.
great weekend all

Comment by fox7mf on Nov 03, 2023 6:33pm
Gobbledygook. Btw, on Yahoo you said the powers that be reiterated that PanCan/PDAC would start "early 2024." The rest of us understood that PanCan was pushed back from Q1 '24 to H1 '24. Did we miss something?
Comment by Buckhenry on Nov 03, 2023 9:30pm
The analyst target.  have had similar numbers the last 3 years for a 12 month analysis... just keep kicking the can down the road... even a blind squirrel finds a nut once in a while I suppose. Many have seemed to lose touch with reality. 
Comment by inthno on Nov 03, 2023 10:04pm
Hello Canada fan and thanks for your synopsis of the cc. I listened again to the webcast and could not find anywhere that Matt or anyone at the company touched on the 90 day agreement. Yes they did say that the precison study trial and grant came late in the game but the 90 days was announced after the precision promise trial was annouinced so had no bearing on the 90 days. If you could direct me ...more  
Comment by fox7mf on Nov 04, 2023 4:58am
We all know Matt is looking for the best offer for Pela. That begs the question: with all the ph1 biotechs getting billions, why can't a multi indication ph3 biotech attract the same? Maybe we are, and the BOD wants more. 
Comment by Journeytc on Nov 04, 2023 11:36am
Fox I doubt ONC is looking for a deal now at least in earnest.   They don't know what they want.  I think they were ready to deal  coming off June but the Bracelet result caught them by surprise.   It's easy to cut a deal.  It should take a minimum of two months of time.  Hire an investment firm,  send out notification of intent, structure a two ...more  
Comment by itntdf on Nov 04, 2023 6:55am
this was taken from oncy's press release: "Oncolytics expects to finalize the definitive agreements within the next 90 days and open the Precision Promise investigational treatment of pelareorep, checkpoint inhibitor, gemcitabine, and nab-paclitaxel in early 2024." no mention was made that inclusion in precision promise came late in the game.  it was clearly stated there was a ...more  
Comment by joeblows on Nov 04, 2023 4:20am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities